Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLYMBullishCorporate Developmentsnews

High materiality7/10

Climb Bio to present CLYM116 and Budoprutug data at ASN Kidney Week 2026

Oct 2, 2026, 9:58 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive data presentations and orphan/fast-track designations commonly drive sentiment and volatility in early-stage biotech names; new data readouts could re-rate risk/reward.

AI summary

What happened, with direct paths to the underlying reporting

Climb Bio announced upcoming ASN Kidney Week 2026 presentations featuring CLYM116 and budoprutug across three kidney diseases, with PrisMN Phase 2 data for budoprutug selected for oral presentation. CLYM116 employs a pH-dependent sweeper mechanism to inhibit APRIL, potentially expanding use beyond IgA nephropathy. Positive early signals and FDA designations for budoprutug could support near-term upside, though data remain early-stage.

Climb Bio to present CLYM116 and budoprutug data at ASN Kidney Week 2026.
PrisMN budoprutug Phase 2 data preliminarily selected for oral presentation Oct 24, 2026.
CLYM116 uses a pH-dependent sweeper mechanism to inhibit APRIL in IgAN.
Budoprutug shows durable B-cell depletion and rapid autoantibody reductions in PMN.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.